支气管扩张症应用噻托溴铵粉吸入剂疗效探讨

Study on Curative Effect of Spiriva for Bronchiectasis

目的分析噻托溴铵粉吸入剂治疗支气管扩张症患者临床效果。方法方便选取2014年1月—2016年1月就诊该院的104例支气管扩张症患者,随机分为对照组和实验组,各52例;对照组采用常规治疗;实验组在常规治疗基础上联合噻托溴铵粉吸入剂,对比分析两组患者肺功能评估指标、症状改善状况、急性加重次数及不良反应。结果(1)在治疗后,实验组MMRC评分为(0.8±0.30)分,6 MWD为(304.6±18.30)m,咳痰评分为(0.9±0.30)分;均与对照组比较差异有统计学意义(P<0.05)。(2)实验组治疗后肺功能IC、FEV1 pred、FVC、FEV1/FVC、MMRC、6 MWD、咳痰、急性加重次数对比治疗前差异有统计学意义(P<0.05)。(3)实验组应用噻托溴铵后1例出现尿潴留停药,8例出现轻微口干。结论在常规治疗基础上联合噻托溴铵粉吸入剂治疗支气管扩张症患者,可以有效的改善患者临床症状,提高治疗有效率,在临床中具有推广和应用价值。

Objective To analyze the clinical effect of Spiriva in treatment of bronchiectasis.Methods Convenient selection104 cases of patients with bronchiectasis diagnosed in our hospital from January 2014 to January 2016 were selected and randomly divided into two groups with 52 cases in each,the control group adopted the routine treatment,while the experimental group adopted the Spiriva on the basis of the routine treatment,and the lung function evaluation index,symptom improvement,acute aggravation time and adverse reactions were compared between the two groups.Results After treatment,the MMRC score,6 MWD and expectoration score were respectively（0.8±0.30）points,（304.6±18.30）m and（0.9±0.30）points,and the differences between groups had statistical significance（P〈0.05）;after treatment,the differences in the lung function IC,FEV1 pred,FVC,FEV1/FVC,MMRC,6 MWD,expectoration and acute aggravation frequency before and after treatment in the test group had statistical significance（P〈0.05）;after the use of tiotropium bromide,there was 1 case with uroschesis drug withdrawal and 8 cases with mild dry in the test group.Conclusion The spiriva on the basis of the routine treatment in treatment of bronchiectasis can effectively improve the clinical symptoms of patients and improve the treatment effective rate,which is of promotion and application value in clinic.